It is now seven years since Krys Bottrill's investigation on the use of botulinum toxin for cosmetic purposes, as well as in medical therapy, led to a brilliant article in ATLA, entitled Growing Old Disgracefully, in which she also expressed concern about the use of the classical LD50 test in the batch testing of this biological product, for whatever purpose. 1 A Web search would suggest that a great deal has happened since then, as all kinds of organisations have become involved in considering the need for animal testing and the prospects for the development of valid replacement alternatives. FRAME has worked in partnership with The Humane Society of the United States (HSUS) to draw attention to this issue, and there have been various workshops, involving, for example, the European Centre for the Validation of Alternative Methods (ECVAM), the US Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), the US Food & Drug Administration (FDA), the European Directorate for the Quality of Medicines and Healthcare (EDQM), and the Federal German Centre for Documentation and Evaluation of Alternatives to Animal Experiments (ZEBET). Meanwhile, a number of laboratories, such as the National Institute for Biological Standards and Control (NIBSC), and the manufacturers of the products, such as Ipsen Limited, have done some very important research on potential replacement alternative tests. I found myself encouraged by all this activity, in the belief that many individuals and institutions of great sincerity and high quality were focusing on the problem, until I was disheartened by three completely different and unrelated events.
Firstly, in September 2009, during the 7th World Congress on Alternatives and Animal Use in the Life Sciences, which took place in Rome, I heard a talk by Sarah Adler on a ZEBET expert meeting on alternative methods to replace the LD50 test for botulinum neurotoxin product testing. 2 There was nothing wrong with the talk itself, but it revealed all kinds of problems which would seem likely to make the search for replacements interminable, such as lack of consensus among regulators, the need for international reference standards and for product-specific validation, and lack of sensitivity of the in vitro assays and their inability to stand alone. Provoked by Martin Stephens of the HSUS, who was sitting beside me and who had been at the ZEBET meeting and various other expert meetings, I commented that, despite all the effort, no agency seemed to be willing to take control and define precisely what needed to be done to make possible the total replacement of the continued and unacceptable use of an old-fashioned and unnecessarily severe version of the LD50 test.
Secondly, in November 2009, the British Union for the Abolition of Vivisection (BUAV) released a bombshell, by revealing what had been discovered during an undercover investigation at Wickham Laboratories, where Ipsen Limited's botulinum toxin product, Dysport ® , is tested. 3 The BUAV claimed that about 74,000 mice a year are subjected to a version of the LD50 test, classified by the Home Office as being of substantial severity, which leads to increasing paralysis, gasping for breath and suffocation. Mice which have not died during the test are killed by carbon dioxide poisoning in a gas chamber or by having their necks broken with a ballpoint pen. It was claimed that this latter procedure sometimes led to the breaking of the backs of the mice, rather than their necks, resulting in inexcusable suffering.
Over the years, despite repeated claims that the UK has the best laboratory animal protection law and regulations in the world, there have been a number of revelations about unacceptable practices in certain individual laboratories. These have often been revealed as a result of undercover investigations of the kind conducted by the BUAV at Wickham Laboratories. FRAME's position on this has been consistent: we do not encourage or condone the use of such tactics, but consider that there is no escape from what they may bring out into the open.
What has been revealed on this occasion is being investigated by the Home Office, and a large number of very serious questions must surely be put to various persons with responsibilities at Wickham Laboratories under the Animals (Scientific Procedures) Act 1986, including the Certificate Holder, the Named Day-to-day Person, the Named Veterinary Surgeon and the Home Office Inspector. Given the severity of the botulinum toxin testing procedure, there should have been strict guidance on what would/would not be permitted, including when the mice should be killed and how they should be killed.
We must await the outcome of the Home Office investigation, but this case serves as an inescapable reminder of the scale of suffering involved in the animal testing of botulinum toxin and of the urgent need for validated non-animal alternative test procedures.
My third source of discouragement was a series of articles in the Body + Soul section of The Times on 20 February 2010, which focused on the use of botulinum toxin for cosmetic purposes. 4 This served as a chilling reminder that the explosion in the use of Ipsen's Dysport ® and Allergan's Botox ® is not related to the therapeutic uses of these products, but to personal vanity and the search for eternal youth. The article said that the latest figures suggest that 472,000 injectable treatments were carried in the UK in one year, an increase of 105% over the previous year.
The article also revealed that there are now concerns about the long-term side-effects of exposure to botulinum toxin, including the possibility, detected in studies on rodents, that toxin injected into the face can reach the brain. It has also been claimed that its use in humans can be addictive, and even that its prolonged use may encourage the formation of new wrinkles! According to The Times, the British Association of Aesthetic Plastic Surgeons has pointed out that if something happens in mice, it does not follow that it will be repeated, or be harmful, in humans. This is not untypical of attitudes toward animal testing, which, on the one hand is considered essential, but which can be dismissed as irrelevant, if the results produced are commercially inconvenient. Common sense would suggest that, since botulinum toxin is one of the most toxic substances ever known, its repeated injection into the face would be likely to have unforeseen consequences.
Much of my hope of a successful outcome to this sad story is invested in the work of Dr Dorothea Sesardic and her colleagues at NIBSC. Early last year, Dr Sesardic wrote an excellent summary of the situation, which is available on the NC3Rs website, 5 in which she concluded that Alternative methods which reduce, refine and replace the use of live animals in testing botulinum toxin therapeutic products are now available. Validation and adoption of these methods will depend on the cooperation of regulatory agencies, manufacturers and validation centres, and will ensure that the 3Rs become an accepted and routine aspect of therapeutic botulinum toxin product testing.
But what is the evidence that this cooperation is taking place, and that the problems identified by Sarah Adler, among others, will be faced up to and overcome? If somebody can tell me, I would be very pleased to hear from them. Meanwhile, the mice will become paralysed and fight for breath, while the glitterati will retain their beauty. What we need is for somebody to step up to take chargeand pledge to smooth out the wrinkles on the road map which points to the desired goal of ending the need for the awful LD50 test.
